Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Insmed Inc Market Cap
The Insmed Inc (INSM) share price is expected to increase by 21.49% over the next year. This is based on calculating the average 12-month share price estimate provided by 8 stock analysts who have covered INSM. Price targets range from $75 at the low end to $103 at the high end. The current analyst consensus for INSM is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Insmed Inc has a total of 8 Wall St Analyst ratings. There are 7 buy ratings, 1 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Insmed Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of INSM.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Josh Schimmer Cantor Fitzgerald | Overweight | Reiterates | Sep 9, 2024 | |
| Andrew Fein HC Wainwright & Co. | Buy | $90 | Reiterates | Aug 29, 2024 |
| Nicole Germino Truist Securities | Buy | $85 | Maintains | Aug 12, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $90 | Reiterates | Aug 12, 2024 |
| Ritu Baral TD Cowen | Buy | $98 | Maintains | Aug 9, 2024 |
| Stephen Willey Stifel | Buy | $88 | Maintains | Aug 9, 2024 |
| Trung Huynh UBS | Buy | $84 | Maintains | Aug 9, 2024 |
| Matthew Harrison Morgan Stanley | Overweight | $85 | Maintains | Jul 12, 2024 |
| Andrea Tan Goldman Sachs | Buy | $102 | Maintains | Jul 10, 2024 |
| Vamil Divan Guggenheim | Buy | $95 | Maintains | Jul 9, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $90 | Maintains | Jul 8, 2024 |
| Jason Zemansky B of A Securities | Buy | $83 | Maintains | Jul 5, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $70 | Reiterates | Jul 2, 2024 |
| Nicole Germino Truist Securities | Buy | $88 | Maintains | Jul 1, 2024 |
| Jason Zemansky B of A Securities | Buy | $83 | Maintains | Jun 28, 2024 |
| Josh Schimmer Evercore ISI Group | Outperform | $75 | Maintains | Jun 21, 2024 |
| Jennifer Kim Cantor Fitzgerald | Overweight | Reiterates | Jun 20, 2024 | |
| Jessica Fye JP Morgan | Overweight | $72 | Maintains | Jun 20, 2024 |
| Graig Suvannavejh Mizuho | Buy | $82 | Maintains | Jun 7, 2024 |
| Stephen Willey Stifel | Buy | $74 | Maintains | Jun 5, 2024 |
When did it IPO
N/A
Staff Count
912
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. William H. Lewis J.D., M.B.A.
Market Cap
$12.59B
In 2023, INSM generated $305.2M in revenue, which was a increase of 24.39% from the previous year. This can be seen as a signal that INSM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 10 Sep 2024
Sentiment - POSITIVE
Source - Schaeffers Research
Summary - Chart of the Week subscribers received a commentary on September 8, providing insights and analysis relevant to market trends and investments.
Why It Matters - The date indicates timely insights, potentially affecting market trends or investment strategies, influencing investor decisions based on recent analysis.
Fri, 06 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Insmed Incorporated granted inducement awards to 60 new employees, highlighting its growth and commitment to attracting talent in the biopharmaceutical sector.
Why It Matters - The granting of inducement awards signals Insmed's growth and commitment to attracting talent, potentially enhancing innovation and long-term value, which can positively impact stock performance.
Wed, 28 Aug 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Insmed's Q2 2024 revenue rose 17% to $90.3M, driven by ARIKAYCE sales. R&D expenses decreased to $146.7M. The U.S. launch of brensocatib is planned for mid-2025, pending Q4 2024 approval.
Why It Matters - Insmed's revenue growth and strong ARIKAYCE sales indicate solid performance. The upcoming brensocatib launch could drive future revenue, while reduced R&D costs improve profitability outlook.
Tue, 27 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - INSM shares rise following positive results from two clinical studies on its lung disorder drugs, indicating progress in their development efforts.
Why It Matters - Positive clinical study results for INSM's lung disorder drugs suggest potential revenue growth and market confidence, leading to increased share value and investment interest.
Sat, 24 Aug 2024
Sentiment - POSITIVE
Source - Investors Business Daily
Summary - Meta and four other stocks are positioned near buy points following a market rally spurred by Fed Chair Jerome Powell's speech on Friday.
Why It Matters - Meta's stock performance and the market's reaction to Powell's speech indicate potential investment opportunities, signaling investor confidence and market trends.
Fri, 09 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Insmed Incorporated (NASDAQ: INSM) will hold its Q2 2024 Earnings Conference Call on August 8, 2024, at 8:00 AM ET with key executives and analysts participating.
Why It Matters - The earnings call indicates upcoming financial performance insights and strategic direction from Insmed's leadership, crucial for assessing investment potential and market sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
